Summit Therapeutics shares are trading lower after hours after closing up over 270% on cancer data.
Portfolio Pulse from Benzinga Newsdesk
Summit Therapeutics shares are trading lower after hours despite closing up over 270% on positive cancer data.
May 30, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Summit Therapeutics shares experienced a significant surge of over 270% due to positive cancer data but are now trading lower after hours.
The initial surge in Summit Therapeutics' stock price was driven by positive cancer data, which is a significant development. However, the after-hours decline suggests profit-taking or market correction, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100